Decoding BRCA1 and BRCA2 Mutations in High-Grade Serous Ovarian Cancer: Impact on Prognosis, Platinum Response, and Actionability

Topography, type, and function of germline BRCA1/2 variants (RING, BRCT, helical domains) correlated with platinum response and survival in HGSOC

This study analyzes the prognostic impact of location, type, and function of germline BRCA1/2 pathogenic variants on survival and platinum response in high-grade serous ovarian cancer (HGSOC). Variants in the BRCA1 BRCT domain and specific BRCA2 regions show significant differences in carboplatin response and overall survival compared to other locations. These genotype-prognosis correlations enable better stratification of BRCA-mutated patients for PARP inhibitor treatments.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Not all germline BRCA1/2 mutations confer the same prognosis or platinum sensitivity. This genotype-phenotype granularity is important for therapeutic stratification (PARP inhibitors) and prognostic genetic counseling. To be integrated in prospective PARP inhibitor efficacy studies stratified by variant location.

Clinical impact: 3/3 · Evidence strength: 2/3 · Novelty: 2/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 9/10